Brief: Citius Pharmaceuticals Announces FDA Acceptance Of The BLA Resubmission Of LYMPHIR™
18/03/2024 13:15
March 18 (Reuters) - Citius Pharmaceuticals Inc
CTXR.O :
* CITIUS PHARMACEUTICALS ANNOUNCES FDA ACCEPTANCE OF THE BLA
RESUBMISSION OF LYMPHIR™ (DENILEUKIN DIFTITOX) FOR THE TREATMENT
OF ADULTS WITH RELAPSED OR REFRACTORY CUTANEOUS T-CELL LYMPHOMA
* CITIUS PHARMACEUTICALS INC -FDA ASSIGNS PRESCRIPTION DRUG
USER
FEE ACT (PDUFA) TARGET ACTION DATE OF AUGUST 13, 2024
Source text for Eikon: ID:nPn6jt1Cga
Further company coverage: CTXR.O
Recent news on Citius Pharmaceuticals
See all newsCitius Pharmaceuticals Q2 revenue rises on LYMPHIR launch
Citius Pharmaceuticals reports first revenue of $3.9 mln
Brief: Citius Oncology Expands International Distribution Of Lymphir™ To European Union Through Exclusive Agreement With Uniphar
Brief: Citius Pharmaceuticals, Inc. Reports Fiscal Year 2025 Financial Results And Provides Business Update
Brief: Citius Oncology Announces $18 Million Concurrent Registered Direct Offering And Private Placement Priced At-The-Market Under Nasdaq Rules